TPIV-100 (TapImmune)

N/A

Report date: 2022/08/29 20:00:24

Base Information

Drug NameTPIV-100 (TapImmune)
Drug Alias NameTPIV-100
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsImmunostimulants
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms, MaleBreast NeoplasmsCarcinoma, Intraductal, Noninfiltrating
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMayo Clinic
China Registration ClassN/A

Develop Information

Active CompaniesMayo Clinic
Inactive CompaniesN/A
Active IndicationsCarcinoma, Intraductal, Noninfiltrating
Inactive IndicationsBreast Neoplasms, MaleBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A